22 Results

People

  1. Mato
    Mato
  2. Palomba
    Palomba
  3. Abdel-Wahab
    Abdel-Wahab
  4. Roeker
    Roeker
  5. Thompson
    Thompson
  6. Zelenetz
    Zelenetz
  7. Aronson
    Aronson
  8. Babady
    Babady
  9. Islam
    Islam
  10. Kamboj
    Kamboj

Groups

  1. Department of Medicine (20)
  2. Hematologic Malignancies, Division of (19)
  3. Center for Hematologic Malignancies (15)
  4. Adult Leukemia (9)
  5. Lymphoma (8)
  6. Executive Committee, Center for Hematologic Malignancies (3)
  7. GME, Medicine (3)
  8. GSK Faculty (3)
  9. Graduate Medical Education (3)
  10. Hematology-Oncology Fellows (3)
  1. "pirtobrutinib"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (5)
  3. Review (5)
  4. Book Section (1)
  5. Conference Paper (1)
  6. Editorial (1)
  7. Research Letter (1)
Groups
  1. Department of Medicine (20)
  2. Hematologic Malignancies, Division of (19)
  3. Center for Hematologic Malignancies (15)
  4. Adult Leukemia (9)
  5. Lymphoma (8)
  6. Executive Committee, Center for Hematologic Malignancies (3)

More Groups

People
  1. Anthony Mato (9)
  2. Lindsey Roeker (8)
  3. Maria Palomba (6)
  4. Meghan Thompson (3)
  5. Omar Abdel-Wahab (3)
  6. Andrew Zelenetz (2)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (7)
  4. 2022 (5)
  5. 2021 (2)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (5)
  2. Haematologica (2)
  3. Advances in Therapy (1)
  4. Blood (1)
  5. British Journal of Haematology (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. Elsevier Inc. (6)
  2. Elsevier Science, Inc. (2)
  3. Ferrata Storti Foundation (2)
  4. Springer (2)
  5. Wiley Blackwell (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I/II BRUIN trial
    Journal Article

    Shah, N. N.; Wang, M.; Roeker, L. E.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells
    Journal Article

    Munshi, M.; Liu, X.; Kofides, A.; Tsakmaklis, N.; Hunter, Z. R.; Guerrera, M. L.; Canning, A.; Gustine, J. N.; Liu, S.; Hatcher, J. M.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
    Review

    Stanchina, M. D.; Montoya, S.; Danilov, A. V.; Castillo, J. J.; Alencar, A. J.; Chavez, J. C.; Cheah, C. Y.; Chiattone, C.; Wang, Y.; Thompson, M.; more...
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy
    Journal Article

    Lamanna, N.; Tam, C. S.; Woyach, J. A.; Alencar, A. J.; Palomba, M. L.; Zinzani, P. L.; Flinn, I. W.; Fakhri, B.; Cohen, J. B.; Kontos, A.; more...
    eJHaem (2024)

    Fulltext@MSK | Save
  • Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: The phase 1b BRUIN trial
    Journal Article

    Roeker, L. E.; Woyach, J. A.; Cheah, C. Y.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M. R.; Lamanna, N.; Tsai, D. E.; Nair, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    Journal Article

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • New means and challenges in the targeting of BTK
    Review

    Nawaratne, V.; Sondhi, A. K.; Abdel-Wahab, O.; Taylor, J.
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison of brexucabtagene autoleucel (ZUMA-2) and pirtobrutinib (BRUIN) in patients with relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor
    Journal Article

    Salles, G.; Chen, J. M. H.; Zhang, I.; Kerbauy, F.; Wu, J. J.; Wade, S. W.; Nunes, A.; Feng, C.; Kloos, I.; Peng, W.; more...
    Advances in Therapy (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK inhibitor pre-treated mantle cell lymphoma: Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Current treatment options in relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: A review
    Review

    Islam, P.
    Current Treatment Options in Oncology (2023)

    Fulltext@MSK | Save